Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'

Incoming CEO at Swiss drugmaker Novartis, Vas Narasimhan, said he isn’t interested in following the herd in drug development.

from Forbes Real Time https://www.forbes.com/sites/michelatindera/2017/11/30/incoming-novartis-ceo-on-475000-cancer-therapy-no-question-that-the-list-price-raises-eyebrows/
via IFTTT